Does coexistence of endometrial cancer and adenomyosis affect survival outcomes? A retrospective cohort study

Latife Gözde Buyuksahin, Azize Cemre ÖZTÜRK, Vakkaş Korkmaz, Şadıman Kıykaç Altınbaş, Yaprak Engin Üstün, O Houri, Y Gil, O Gemer, L Helpman, Z Vaknin, O Lavie, B Pecorino, A Lagan, V Chiantera, M Ferrara, Di Stefano, A, Di Donna, M, A Lindfors, H Heshar, C Adok, K Sundfeldt, P Dahm-Khler, K Matsuo, S Matsuzaki, D Nusbaum, H Machida, Y Nagase, B Grubbs, C. Chapron, S. Vannuccini, M Abro, F Carmona, I Fraser, M Hermens, A Van Altena, I Velthuis, Dcm Van De Laar, Haam Van Vliet, M. Bourdon, P Santulli, L Marcellin, C Maignien, L Maitrot-Mantelet, C Bordonne, X. Li, X. Liu, S Guo, M Van Der Aa, J Bulten, A Siebers, K Hanley, S Dustin, M Stoler, K Atkins, C. Bergeron, F Amant, A Ferenczy, I Rowlands, C Nagle, A Spurdle, P Webb, M An, H Duan, Y Zhang, M Szubert, E Kozirog, J Wilczynski, A Yilmaz, H Cokmez, A Gulbahar, J Da Silva, M Andres, Apk Leite, Mtna Gomes, J Neto, E Baracat, C Palena, D Hamilton, R Fernando, K Aslan, M. Sar, H Yaln, Yaln, Z Cylan, B zdal, gder, H Doru, A zsoy, B akmak, Deliba, A Arici, K Upson, S Missmer, S Bulun, S Yildiz, M Adli, J Wei, K Khan, A Fujishita, T Mori, N Pan, W Zhang, Y Wang, Y Ge, H Wei, H Hu, H Li, Y He, M Maeda, S Cahoon, C Scannell, J Garcia-Sayre, L. Roman, S Johnatty, Cjr Stewart, D Smith, A Nguyen, O' Dwyer, J, O 'mara, T, J. Yun, L Jong-Min, Y Seung, A Taneichi, H. Fujiwara, Y. Takahashi, Y Takei, S Machida, Y Saga, A Raffone, A Travaglino, D. Raimondo, M. Maletta, P Salucci, A Santoro, A Murphy, H Campo, J. Kim, F Musa, M Frey, H Im, M Chekmareva, L Ellenson, K Holcomb, M. Gualtieri, C Jung, T Takano, M Koshiyama, T Okamoto, M Ueta, X Mao, W Zheng, W Mao, S Boonlak, A Aue-Aungkul, C Kietpeerakool, P Kleebkaow, B Chumworathayi, S Luanratanakorn
In: European Journal of Gynaecological Oncology · 2023 · doi:10.22514/ejgo.2023.112 · W4390240397
article OA: diamond CC0 ⤵ 1 in-corpus citation
📄 Open PDF Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This study found that the coexistence of adenomyosis with endometrial cancer did not significantly impact overall survival or disease-free survival in patients undergoing hysterectomy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text ⓘ

This retrospective cohort study examined whether coexistence of adenomyosis in pathology specimens modifies survival outcomes among women treated for endometrial carcinoma at a tertiary center between 2010 and 2016. Of 370 patients with endometrial carcinoma who underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy, adenomyosis was present in 76 and absent in 287 after pathology review, and overall survival and disease-free survival were compared using mortality and time-to-death metrics. Mortality rates (9.2% vs 12.9%) and mean time from diagnosis to death (29.3 vs 44.6 months) did not differ significantly, and adenomyosis was not associated with overall survival (p=0.434) or disease-free survival (p=0.146). The authors’ main limitation is the retrospective, single-center design with the relatively small adenomyosis subgroup. This paper is centrally about adenomyosis in endometrial cancer and evaluates how adenomyosis coexistence affects survival outcomes.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

The aim of this study is to investigate cancer survival parameters in patients with a combination of adenomyosis and endometrial carcinoma in pathological specimens. This is a retrospective cohort study conducted in a tertiary health center. Between January 2010 and December 2016, a total of 370 patients with a diagnosis of endometrial carcinoma who had undergone at least total abdominal hysterectomy and bilateral salpingoopherectomy. After excluding the patients from the pathology after reviewing the reports, 76 patients with adenomyosis were included in the study group and 287 patients without adenomyosis were included in the control group. The mean age of all patients was 63.6 ± 8.2 years. The mortality rate was 9.2% in patients with adenomyosis and 12.9% in patients without adenomyosis (p = 0.382). Overall, the mean time from diagnosis to death was 41.8 ± 24.7 months, which did not differ between patients with adenomyosis (29.3 ± 18 months) and without adenomyosis (44.6 ± 25.4 months, (p = 0.117). The presence of adenomyosis did not significantly affect overall survival (p = 0.434) or disease-free survival (p = 0.146). Median disease-free survival was 119 months in patients without adenomyosis and 120 months in patients with adenomyosis. None of the factors we studied affected survival in patients with adenomyosis. In our study, the presence of adenomyosis was found in 20.9% of patients who underwent hysterectomy for endometrial cancer, and this association had neither a positive nor a negative impact on disease prognosis, i.e., mortality rate, disease-free survival and overall survival.
Full text 10,407 characters · extracted from oa-doi-fallback · click to expand
Title Author DOI Article Type Special Issue Volume Issue Search - Views 5694 - Dowloads 192 Does coexistence of endometrial cancer and adenomyosis affect survival outcomes? A retrospective cohort study - Latife Gözde Buyuksahin1 - Mujde Can Ibanoglu1,*, - Azize Cemre Ozturk1 - Vakkas Korkmaz1 - Sadiman Kiykac Altinbas1 - Yaprak Engin-Ustun1 1Department of Gynecology, Ankara Etlik Zubeyde Hanım Women’s Health Training and Research Hospital, 06000 Ankara, Turkey DOI: 10.22514/ejgo.2023.112 Vol.45,Issue 2,April 2024 pp.118-126 Submitted: 03 August 2023 Accepted: 08 October 2023 Published: 15 April 2024 *Corresponding Author(s): Mujde Can Ibanoglu E-mail: [email protected] The aim of this study is to investigate cancer survival parameters in patients with a combination of adenomyosis and endometrial carcinoma in pathological specimens. This is a retrospective cohort study conducted in a tertiary health center. Between January 2010 and December 2016, a total of 370 patients with a diagnosis of endometrial carcinoma who had undergone at least total abdominal hysterectomy and bilateral salpingoopherectomy. After excluding the patients from the pathology after reviewing the reports, 76 patients with adenomyosis were included in the study group and 287 patients without adenomyosis were included in the control group. The mean age of all patients was 63.6 ± 8.2 years. The mortality rate was 9.2% in patients with adenomyosis and 12.9% in patients without adenomyosis (p = 0.382). Overall, the mean time from diagnosis to death was 41.8 ± 24.7 months, which did not differ between patients with adenomyosis (29.3 ± 18 months) and without adenomyosis (44.6 ± 25.4 months, (p = 0.117). The presence of adenomyosis did not significantly affect overall survival (p = 0.434) or disease-free survival (p = 0.146). Median disease-free survival was 119 months in patients without adenomyosis and 120 months in patients with adenomyosis. None of the factors we studied affected survival in patients with adenomyosis. In our study, the presence of adenomyosis was found in 20.9% of patients who underwent hysterectomy for endometrial cancer, and this association had neither a positive nor a negative impact on disease prognosis, i.e., mortality rate, disease-free survival and overall survival. Adenomyosis; Endometrial carcinoma; Prognostic factor; Survive Latife Gözde Buyuksahin,Mujde Can Ibanoglu,Azize Cemre Ozturk,Vakkas Korkmaz,Sadiman Kiykac Altinbas,Yaprak Engin-Ustun. Does coexistence of endometrial cancer and adenomyosis affect survival outcomes? A retrospective cohort study. European Journal of Gynaecological Oncology. 2024. 45(2);118-126. [1] Houri O, Gil Y, Gemer O, Helpman L, Vaknin Z, Lavie O, et al. Prediction of endometrial cancer recurrence by using a novel machine learning algorithm: an Israeli gynecologic oncology group study. Journal of Gynecology Obstetrics and Human Reproduction. 2022; 51: 102466. [2] Pecorino B, Laganà AS, Chiantera V, Ferrara M, Di Stefano AB, Di Donna MC, et al. Progression free survival, overall survival, and relapse rate in endometrioid ovarian cancer and synchronous endometrial-ovarian endometrioid cancer (SEO-EC): results from a large retrospective analysis. Medicina. 2022; 58: 1706. [3] Lindfors A, Heshar H, Adok C, Sundfeldt K, Dahm-Kähler P. Long-term survival in obese patients after robotic or open surgery for endometrial cancer. Gynecologic Oncology. 2020; 158: 673–680. [4] Matsuo K, Matsuzaki S, Nusbaum DJ, Machida H, Nagase Y, Grubbs BH, et al. Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer. European Journal of Cancer. 2020; 133: 33–46. [5] Chapron C, Vannuccini S, Santulli P, Abrão MS, Carmona F, Fraser IS, et al. Diagnosing adenomyosis: an integrated clinical and imaging approach. Human Reproduction Update. 2020; 26: 392–411. [6] Hermens M, van Altena AM, Velthuis I, van de Laar DCM, Bulten J, van Vliet HAAM, et al. Endometrial cancer incidence in endometriosis and adenomyosis. Cancers. 2021; 13: 4592. [7] Bourdon M, Santulli P, Marcellin L, Maignien C, Maitrot-Mantelet L, Bordonne C, et al. Adenomyosis: an update regarding its diagnosis and clinical features. Journal of Gynecology Obstetrics and Human Reproduction. 2021; 50: 102228. [8] Li X, Liu X, Guo SW. Clinical profiles of 710 premenopausal women with adenomyosis who underwent hysterectomy. Journal of Obstetrics and Gynaecology Research. 2014; 40: 485–494. [9] Hermens M, van Altena AM, van der Aa M, Bulten J, van Vliet HAAM, Siebers AG, et al. Endometrial cancer prognosis in women with endometriosis and adenomyosis: a retrospective nationwide cohort study of 40 840 women. International Journal of Cancer. 2022; 150: 1439–1446. [10] Hanley KZ, Dustin SM, Stoler MH, Atkins KA. The significance of tumor involved adenomyosis in otherwise low-stage endometrioid adenocarcinoma. International Journal of Gynecological Pathology. 2010; 29: 445–451. [11] Bergeron C, Amant F, Ferenczy A. Pathology and physiopathology of adenomyosis. Best Practice & Research Clinical Obstetrics & Gynaecology. 2006; 20: 511–521. [12] Rowlands IJ, Nagle CM, Spurdle AB, Webb PM. Gynecological conditions and the risk of endometrial cancer. Gynecologic Oncology. 2011; 123: 537–541. [13] An M, Duan H, Zhang Y. Prognostic significance of co-existent adenomyosis on outcomes and tumor characteristics of endometrial cancer: a meta-analysis. Journal of Obstetrics and Gynaecology Research. 2020; 46: 1851–1863. [14] Szubert M, Kozirog E, Wilczynski J. Adenomyosis as a risk factor for myometrial or endometrial neoplasms-review. International Journal of Environmental Research and Public Health. 2022; 19: 2294. [15] Yilmaz A, Cokmez H, Gulbahar A. Effect of coexisting adenomyosis on patients with endometrioid adenocarcinoma: Determination of intraoperative risk factors for tumor metastasis and estimation of prognosis. Journal of Cancer Research and Therapeutics. 2022; 18: 599–602. [16] da Silva JR, Andres MP, Leite APK, Gomes MTNA, Neto JS, Baracat EC, et al. Comparison of sensitivity and specificity of structured and narrative reports of transvaginal ultrasonogaphy for adenomyosis. Journal of Minimally Invasive Gynecology. 2021; 28: 1216–1224. [17] Palena C, Hamilton DH, Fernando RI. Infuence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncology. 2012; 8: 713–722. [18] Aslan K, Sarı ME, Yalçın HR, Yalçın İ, Cüylan ZF, Özdal B. Coexistence of uterine adenomyosis is not associated with a better prognosis in endometrioid-type endometrial cancer. Irish Journal of Medical Science. 2020; 189: 835–842. [19] İşgüder ÇK, Doğru HY, Özsoy AZ, Çakmak B, Delibaş İB, Arici A, et al. The Evaluation of Histopathological Diagnosis in Hysterectomy Materials. Journal of Contemporary Medicine. 2016; 6: 87–91. [20] Upson K, Missmer SA. Epidemiology of adenomyosis. Seminars in Reproductive Medicine. 2020; 38: 89–107. [21] Bulun SE, Yildiz S, Adli M, Wei JJ. Adenomyosis pathogenesis: insights from next-generation sequencing. Human Reproduction Update. 2021; 27: 1086–1097. [22] Khan KN, Fujishita A, Mori T. Pathogenesis of human adenomyosis: current understanding and its association with infertility. Journal of Clinical Medicine. 2022; 11: 4057. [23] Li X, Pan N, Zhang W, Wang Y, Ge Y, Wei H, et al. Association between uterine volume and pregnancy outcomes in adenomyosis patients undergoing frozen-thawed embryo transfer. Reproductive BioMedicine Online. 2021; 42: 384–389. [24] Hu H, Li H, He Y. MicroRNA-17 downreguates expression of the PTEN gene to promote the occurrence and development of adenomyosis. Experimental and Therapeutic Medicine. 2017; 14: 3805–3811. [25] Machida H, Maeda M, Cahoon SS, Scannell CA, Garcia-Sayre J, Roman LD, et al. Endometrial cancer arising in adenomyosis versus endometrial cancer coexisting with adenomyosis: are these two diferent entities? Archives of Gynecology and Obstetrics. 2017; 295: 1459–1468. [26] Johnatty SE, Stewart CJR, Smith D, Nguyen A, O' Dwyer J, O’Mara TA, et al. Co-existence of leiomyomas, adenomyosis and endometriosis in women with endometrial cancer. Scientific Reports. 2020; 10: 3621. [27] Yun JB, Jong-Min L, Seung YP. Endometrial adenocarcinoma arising in adenomyosis: case report and review of literature. European Journal of Gynaecological Oncology. 2020; 41: 858–862. [28] Taneichi A, Fujiwara H, Takahashi Y, Takei Y, Machida S, Saga Y, et al. Influences of uterine adenomyosis on muscle invasion and prognosis of endometrioid adenocarcinoma. International Journal of Gynecologic Cancer. 2014; 24: 1429–1433. [29] Raffone A, Travaglino A, Raimondo D, Maletta M, Salucci P, Santoro A, et al. Histological prognostic factors of endometrial cancer in patients with adenomyosis: a systematic review and meta-analysis. Pathobiology. 2022; 89: 127–134. [30] Murphy AR, Campo H, Kim JJ. Strategies for modelling endometrial diseases. Nature Reviews Endocrinology. 2022; 18: 727–743. [31] Musa F, Frey MK, Im HB, Chekmareva M, Ellenson LH, Holcomb K. Does the presence of adenomyosis and lymphovascular space invasion affect lymph node status in patients with endometrioid adenocarcinoma of the endometrium? American Journal of Obstetrics and Gynecology. 2012; 207: 417.e1–417.e6. [32] Matsuo K, Cahoon SS, Gualtieri M, Scannell CA, Jung CE, Takano T, et al. Signifcance of adenomyosis on tumor progression and survival outcome of endometrial cancer. Annals of Surgical Oncology. 2014; 21: 4246–4255. [33] Koshiyama M, Okamoto T, Ueta M. The relationship between endometrial carcinoma and coexistent adenomyosis uteri, endometriosis externa and myoma uteri. Cancer Detection and Prevention. 2004; 28: 94–98. [34] Mao X, Zheng W, Mao W. Malignant changes in adenomyosis in patients with endometrial adenocarcinoma: a case series. Medicine. 2017; 96: e8336. [35] Boonlak S, Aue-Aungkul A, Kietpeerakool C, Kleebkaow P, Chumworathayi B, Luanratanakorn S, et al. Impact of coexisting uterine adenomyosis on the survival outcome of patients with endometrial cancer: a retrospective cohort study. Asian Pacific Journal of Cancer Prevention. 2019; 20: 1185–1190. [36] Zouzoulas OD, Tsolakidis D, Efstratiou I, Pervana S, Pazarli E, Grimbizis G. Correlation between adenomyosis and endometrial cancer: 6-year experience of a single center. Facts, Views & Vision in ObGyn. 2018; 10: 147–152. Top

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (36)

Cited by (2)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK